

- 13 -

Patent Claims

1. Stable formulation of a solution consisting of
xylometazoline hydrochloride and oxymetazoline
hydrochloride as active substance, a solvent which is
pharmacologically acceptable for nasal
administration, an adjuvant selected from among
sorbitol and/or glycerol and an inorganic pH buffer.
2. Formulation according to claim 1, characterised in
that the active substance is present in a
concentration of between 0.01 and 1.0% by weight,
preferably between 0.01 and 0.5% by weight and most
preferably between 0.05 and 0.1% by weight.
3. Formulation according to one of claims 1 and 2,
characterised in that the solvent is water.
4. Formulation according to one of claims 1 and 2,
characterised in that the solvent is a mixture of
ethanol and water.
5. Formulation according to one of claims 1 to 4,
characterised in that the proportion of adjuvant in
the solution is 1 to 10% by weight, preferably 2 to
6% by weight.
6. Formulation according to claim 5, characterised in
that the adjuvant is 3.5 to 4.5% by weight,
preferably 4.0% by weight, of sorbitol.
7. Formulation according to claim 6, characterised in
that the adjuvant is 2.0 to 2.8% by weight,
preferably 2.4% by weight, of glycerol.

- 14 -

8. Formulation according to one of claims 1 to 7,
characterised in that the solution contains a sodium
and/or potassium phosphate buffer or a sodium and/or
potassium borate buffer.
- 5
9. Formulation according to one of claims 1 to 8,
characterised in that the solution contains a
monosodium dihydrogen-disodium monohydrogen phosphate
buffer and/or monopotassium dihydrogen-dipotassium
monohydrogen phosphate buffer.
- 10
10. Formulation according to one of claims 1 to 9,
characterised in that the solution is adjusted to a
pH of 5.0 to 6.8, preferably 5.5 to 6.8, most
preferably 5.8 to 6.0.
- 15
11. Formulation according to one of claims 1 to 10,
characterised in that the formulation contains an
oligodynamically active substance.
- 20
12. Formulation according to claim 11, characterised in
that the oligodynamic substance is silver or silver
ions.
- 25
13. Formulation according to one of claims 1 to 12,
characterised in that the formulation contains only
xylometazoline hydrochloride as active substance.
- 30
14. Formulation according to one of claims 1 to 12,
characterised in that the formulation contains only
oxymetazoline hydrochloride as active substance.
- 35
15. Use of a formulation according to claims 1 to 14
together with an inhaler having silver-containing
elements in the region between the active substance
reservoir and the sprayhead.

- 15 -

16. Use of the formulation according to one of claims 1 to 13 as a rhinological agent.